Astrazeneca Plc · LSE:AZN
Astrazeneca — Investor Presentation (1999)
6 slides from Astrazeneca's investor presentation, 1999
Slide 1: AstraZeneca Infection
AstraZeneca Infection Aileen Allsop Vice President & Head of Infectious Disease TA Anti-infectives portfolio
Slide 2: Infectious disease
Infectious disease h Why should we be interested? h What can we do about it? “Changing market = “New technologies = Unmet medical need” New drugs” New opportunities Global infection market $37bn h 14% of total pharmaceutical sales
Slide 3: World anti-infective market and the problems of resistance
World anti-infective market Global infection market split by major region: 1Q 99 Total market growth forecast +10% 6% LA 3% + n 4b % 30% Europe 46% $2 15 USA 6% + + Japan Antibacterial Antifungal Antiviral Others 18% Source : WinEi Antibacterials dominate Hospital market for antibiotics 35% hospital
Slide 4: Building our infection franchise for the future
Building our infection franchise for the future Merrem®/Meronem® - the best broad-spectrum treatment for serious infection AZD 2563 - a novel oxazolidinone, a new class of antibiotics Oxazolidinones - a new style of antibiotic A new mechanism of action! h New drug class - active against some of the
Slide 5: Building our franchise for the future
Building our franchise for the future h Merrem®/Meronem® - the best broad-spectrum treatment for serious infection h AZD 2563 - a novel oxazolidinone, a new class of antibiotics Discovery - competitive platform in genomics-based drug hunting technologies 10 new targets in screening Genomics - the ke
Slide 6: Infection - building the franchise
Infection - building the franchise Horizon 2 Second - consolidate and extend the serious infection franchise 2002 2007 Horizon 1 Horizon 3 First - deliver foundation From this commercial based on current assets platform, using compounds from AstraZeneca research move into primary care